

# **Crohn's Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulator, Other), By Application (Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region & Competition, 2021-2031F**

<https://marketpublishers.com/r/C0D7AF7A75E4EN.html>

Date: January 2026

Pages: 180

Price: US\$ 4,500.00 (Single User License)

ID: C0D7AF7A75E4EN

## **Abstracts**

The Global Crohn's Disease Treatment Market is projected to expand from USD 12.04 Billion in 2025 to USD 15.31 Billion by 2031, reflecting a compound annual growth rate of 4.09%. This market comprises a range of pharmaceutical interventions, such as immunomodulators, antibiotics, and biologic therapies, all aimed at inducing and maintaining remission in patients suffering from this chronic inflammatory condition. Growth is primarily driven by the rising prevalence of the disease in industrialized nations and the continued approval of new therapeutic agents. Data from the Crohn's & Colitis Foundation in 2024 indicates that approximately 100,429 American youths under the age of 20 are living with Inflammatory Bowel Disease, with Crohn's disease notably more prevalent than ulcerative colitis in this demographic, highlighting the expanding need for ongoing medical management.

However, the market faces significant obstacles due to the high costs associated with advanced biologic therapies, which frequently create barriers to patient access and

reimbursement. Strict regulatory requirements and the substantial financial burden of continuous treatment plans can delay the adoption of effective medications, particularly in regions with limited healthcare budgets. Consequently, these economic pressures may restrict the market penetration of premium therapeutic options, compelling healthcare providers to rely on older and less expensive alternatives.

## **Market Driver**

The primary catalyst for market expansion is the relentlessly increasing global prevalence and incidence of Crohn's disease. This growing disease burden is no longer limited to Western nations but is visibly accelerating in newly industrializing regions, driven by shifting environmental factors and lifestyle changes. The expansion of the patient pool necessitates long-term, continuous medical management, thereby ensuring sustained demand for therapeutic interventions. Underscoring the immense scale of the population requiring effective treatment, the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) noted in their 'World IBD Day Report 2025' that there are currently over 10 million people worldwide living with inflammatory bowel diseases.

Simultaneously, the market is being reshaped by the rapid adoption of advanced biologics and the approval of novel drug classes that offer superior efficacy and safety profiles compared to legacy therapies. Healthcare providers are increasingly transitioning patients to next-generation mechanisms, such as interleukin inhibitors, to achieve deeper remission, which drives significant revenue growth for innovative formulations. Financial data substantiates this trend; according to AbbVie's January 2025 report, global net revenues for the advanced therapy Skyrizi reached \$11.7 billion for the full year 2024. Similarly, Johnson & Johnson reported that the established biologic Stelara generated \$10.4 billion in sales during 2024, illustrating the massive scale of investment in biologic care despite mounting pressure from newer entrants and biosimilars.

## **Market Challenge**

The high cost of advanced biologic therapies constitutes a substantial barrier impeding the expansion of the Global Crohn's Disease Treatment Market. While these drugs offer efficacy, their pricing structures create severe accessibility issues for patients and strain healthcare budgets. Insurance providers frequently implement strict reimbursement protocols, such as step therapy, compelling patients to fail on cheaper alternatives before approving premium treatments. This financial toxicity discourages

adherence and delays the initiation of optimal care, directly reducing the revenue potential for advanced therapeutic agents.

The economic strain on the patient population is quantifiable and severe. According to the Crohn's & Colitis Foundation, in 2024, more than 40% of inflammatory bowel disease patients made significant financial sacrifices to afford their healthcare. Furthermore, 63% of patients prescribed medication reported facing specific financial barriers that prevented them from obtaining their treatment. This inability to afford prescribed regimens limits the market penetration of high-value biologics and forces a market reliance on lower-cost generics or biosimilars.

## **Market Trends**

The accelerating adoption of cost-effective biosimilars is fundamentally restructuring the Global Crohn's Disease Treatment Market by introducing affordable alternatives to high-priced legacy biologics. As patent exclusivities for major monoclonal antibodies expire, regulatory bodies are expediting the approval of biosimilar candidates, which mitigates the financial barriers currently restricting patient access to biologic therapy. This influx of lower-cost options is compelling payers to adjust formulary structures, thereby driving market penetration in cost-sensitive regions and challenging the dominance of originator drugs. According to an AscellaHealth report from January 2025, the FDA approved six distinct biosimilars for the blockbuster drug Stelara in 2024 alone, signaling a massive shift in prescription volume toward these economical therapeutic options.

Concurrently, the shift toward oral small molecule therapeutics is redefining treatment paradigms by offering potent efficacy combined with the convenience of pill-based administration. Unlike traditional biologics that require subcutaneous or intravenous delivery, advanced Janus kinase (JAK) inhibitors and S1P receptor modulators provide patients with a non-invasive option that significantly improves lifestyle flexibility and adherence. This transition is rapidly gaining momentum as clinical data demonstrates that these oral therapies can achieve remission rates comparable to injectable biologics. Highlighting this demand, AbbVie reported in January 2025 that global net revenues for the oral JAK inhibitor Rinvoq reached \$6.0 billion for the full year 2024, reflecting robust growth for convenient, advanced therapeutic mechanisms.

## **Key Market Players**

Eli Lilly and Company

AbbVie Inc.

AstraZeneca plc

Boehringer Ingelheim GmbH

Celgene Corporation

Novartis AG

Sanofi SA

Takeda Pharmaceutical Company Limited

Mylan N.V.

Amgen Inc

## **Report Scope**

In this report, the Global Crohn's Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

### **Crohn's Disease Treatment Market, By Drug Type**

Antibiotics

Amino Salicylates

Corticosteroids

Immunomodulator

Other

### **Crohn's Disease Treatment Market, By Application**

Neuropathic Pain

Fibromyalgia

Chronic Back Pain

Arthritic Pain

Migraine Post-Operative Pain

Cancer Pain

Other

#### Crohn's Disease Treatment Market, By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

#### Crohn's Disease Treatment Market, By Region

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

## **Competitive Landscape**

Company Profiles: Detailed analysis of the major companies present in the Global Crohn's Disease Treatment Market.

**Available Customizations:**

Global Crohn's Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

**Company Information**

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. VOICE OF CUSTOMER

### 5. GLOBAL CROHN'S DISEASE TREATMENT MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Drug Type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulator, Other)
  - 5.2.2. By Application (Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other)

5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

5.2.4. By Region

5.2.5. By Company (2025)

5.3. Market Map

## **6. NORTH AMERICA CROHN'S DISEASE TREATMENT MARKET OUTLOOK**

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Drug Type

6.2.2. By Application

6.2.3. By Distribution Channel

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Crohn's Disease Treatment Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Drug Type

6.3.1.2.2. By Application

6.3.1.2.3. By Distribution Channel

6.3.2. Canada Crohn's Disease Treatment Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Drug Type

6.3.2.2.2. By Application

6.3.2.2.3. By Distribution Channel

6.3.3. Mexico Crohn's Disease Treatment Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Drug Type

6.3.3.2.2. By Application

6.3.3.2.3. By Distribution Channel

## **7. EUROPE CROHN'S DISEASE TREATMENT MARKET OUTLOOK**

- 7.1. Market Size & Forecast
  - 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Drug Type
  - 7.2.2. By Application
  - 7.2.3. By Distribution Channel
  - 7.2.4. By Country
- 7.3. Europe: Country Analysis
  - 7.3.1. Germany Crohn's Disease Treatment Market Outlook
    - 7.3.1.1. Market Size & Forecast
      - 7.3.1.1.1. By Value
    - 7.3.1.2. Market Share & Forecast
      - 7.3.1.2.1. By Drug Type
      - 7.3.1.2.2. By Application
      - 7.3.1.2.3. By Distribution Channel
  - 7.3.2. France Crohn's Disease Treatment Market Outlook
    - 7.3.2.1. Market Size & Forecast
      - 7.3.2.1.1. By Value
    - 7.3.2.2. Market Share & Forecast
      - 7.3.2.2.1. By Drug Type
      - 7.3.2.2.2. By Application
      - 7.3.2.2.3. By Distribution Channel
  - 7.3.3. United Kingdom Crohn's Disease Treatment Market Outlook
    - 7.3.3.1. Market Size & Forecast
      - 7.3.3.1.1. By Value
    - 7.3.3.2. Market Share & Forecast
      - 7.3.3.2.1. By Drug Type
      - 7.3.3.2.2. By Application
      - 7.3.3.2.3. By Distribution Channel
  - 7.3.4. Italy Crohn's Disease Treatment Market Outlook
    - 7.3.4.1. Market Size & Forecast
      - 7.3.4.1.1. By Value
    - 7.3.4.2. Market Share & Forecast
      - 7.3.4.2.1. By Drug Type
      - 7.3.4.2.2. By Application
      - 7.3.4.2.3. By Distribution Channel
  - 7.3.5. Spain Crohn's Disease Treatment Market Outlook
    - 7.3.5.1. Market Size & Forecast

- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
  - 7.3.5.2.1. By Drug Type
  - 7.3.5.2.2. By Application
  - 7.3.5.2.3. By Distribution Channel

## **8. ASIA PACIFIC CROHN'S DISEASE TREATMENT MARKET OUTLOOK**

- 8.1. Market Size & Forecast
  - 8.1.1. By Value
- 8.2. Market Share & Forecast
  - 8.2.1. By Drug Type
  - 8.2.2. By Application
  - 8.2.3. By Distribution Channel
  - 8.2.4. By Country
- 8.3. Asia Pacific: Country Analysis
  - 8.3.1. China Crohn's Disease Treatment Market Outlook
    - 8.3.1.1. Market Size & Forecast
      - 8.3.1.1.1. By Value
    - 8.3.1.2. Market Share & Forecast
      - 8.3.1.2.1. By Drug Type
      - 8.3.1.2.2. By Application
      - 8.3.1.2.3. By Distribution Channel
  - 8.3.2. India Crohn's Disease Treatment Market Outlook
    - 8.3.2.1. Market Size & Forecast
      - 8.3.2.1.1. By Value
    - 8.3.2.2. Market Share & Forecast
      - 8.3.2.2.1. By Drug Type
      - 8.3.2.2.2. By Application
      - 8.3.2.2.3. By Distribution Channel
  - 8.3.3. Japan Crohn's Disease Treatment Market Outlook
    - 8.3.3.1. Market Size & Forecast
      - 8.3.3.1.1. By Value
    - 8.3.3.2. Market Share & Forecast
      - 8.3.3.2.1. By Drug Type
      - 8.3.3.2.2. By Application
      - 8.3.3.2.3. By Distribution Channel
  - 8.3.4. South Korea Crohn's Disease Treatment Market Outlook
    - 8.3.4.1. Market Size & Forecast

- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
  - 8.3.4.2.1. By Drug Type
  - 8.3.4.2.2. By Application
  - 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Crohn's Disease Treatment Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Type
    - 8.3.5.2.2. By Application
    - 8.3.5.2.3. By Distribution Channel

## **9. MIDDLE EAST & AFRICA CROHN'S DISEASE TREATMENT MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Drug Type
  - 9.2.2. By Application
  - 9.2.3. By Distribution Channel
  - 9.2.4. By Country
- 9.3. Middle East & Africa: Country Analysis
  - 9.3.1. Saudi Arabia Crohn's Disease Treatment Market Outlook
    - 9.3.1.1. Market Size & Forecast
      - 9.3.1.1.1. By Value
    - 9.3.1.2. Market Share & Forecast
      - 9.3.1.2.1. By Drug Type
      - 9.3.1.2.2. By Application
      - 9.3.1.2.3. By Distribution Channel
  - 9.3.2. UAE Crohn's Disease Treatment Market Outlook
    - 9.3.2.1. Market Size & Forecast
      - 9.3.2.1.1. By Value
    - 9.3.2.2. Market Share & Forecast
      - 9.3.2.2.1. By Drug Type
      - 9.3.2.2.2. By Application
      - 9.3.2.2.3. By Distribution Channel
  - 9.3.3. South Africa Crohn's Disease Treatment Market Outlook
    - 9.3.3.1. Market Size & Forecast

- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
  - 9.3.3.2.1. By Drug Type
  - 9.3.3.2.2. By Application
  - 9.3.3.2.3. By Distribution Channel

## **10. SOUTH AMERICA CROHN'S DISEASE TREATMENT MARKET OUTLOOK**

- 10.1. Market Size & Forecast
  - 10.1.1. By Value
- 10.2. Market Share & Forecast
  - 10.2.1. By Drug Type
  - 10.2.2. By Application
  - 10.2.3. By Distribution Channel
  - 10.2.4. By Country
- 10.3. South America: Country Analysis
  - 10.3.1. Brazil Crohn's Disease Treatment Market Outlook
    - 10.3.1.1. Market Size & Forecast
      - 10.3.1.1.1. By Value
    - 10.3.1.2. Market Share & Forecast
      - 10.3.1.2.1. By Drug Type
      - 10.3.1.2.2. By Application
      - 10.3.1.2.3. By Distribution Channel
  - 10.3.2. Colombia Crohn's Disease Treatment Market Outlook
    - 10.3.2.1. Market Size & Forecast
      - 10.3.2.1.1. By Value
    - 10.3.2.2. Market Share & Forecast
      - 10.3.2.2.1. By Drug Type
      - 10.3.2.2.2. By Application
      - 10.3.2.2.3. By Distribution Channel
  - 10.3.3. Argentina Crohn's Disease Treatment Market Outlook
    - 10.3.3.1. Market Size & Forecast
      - 10.3.3.1.1. By Value
    - 10.3.3.2. Market Share & Forecast
      - 10.3.3.2.1. By Drug Type
      - 10.3.3.2.2. By Application
      - 10.3.3.2.3. By Distribution Channel

## **11. MARKET DYNAMICS**

- 11.1. Drivers
- 11.2. Challenges

## **12. MARKET TRENDS & DEVELOPMENTS**

- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments

## **13. GLOBAL CROHN'S DISEASE TREATMENT MARKET: SWOT ANALYSIS**

## **14. PORTER'S FIVE FORCES ANALYSIS**

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products

## **15. COMPETITIVE LANDSCAPE**

- 15.1. Eli Lilly and Company
  - 15.1.1. Business Overview
  - 15.1.2. Products & Services
  - 15.1.3. Recent Developments
  - 15.1.4. Key Personnel
  - 15.1.5. SWOT Analysis
- 15.2. AbbVie Inc.
- 15.3. AstraZeneca plc
- 15.4. Boehringer Ingelheim GmbH
- 15.5. Celgene Corporation
- 15.6. Novartis AG
- 15.7. Sanofi SA
- 15.8. Takeda Pharmaceutical Company Limited
- 15.9. Mylan N.V.
- 15.10. Amgen Inc

## **16. STRATEGIC RECOMMENDATIONS**

## 17. ABOUT US & DISCLAIMER

## I would like to order

Product name: Crohn's Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulator, Other), By Application (Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region & Competition, 2021-2031F

Product link: <https://marketpublishers.com/r/C0D7AF7A75E4EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C0D7AF7A75E4EN.html>